Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the LUX-Lung 7 Trial (Spanish Language Version) 
2016 ESMO CongressLuis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses in Spanish overall survival data on afatinib vs gefitinib in patients with EGFR mutation–positive non–small cell lung cancer. (Abstract LBA43)
Related Videos
Mansoor Raza Mirza, MD, on Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial
Mansoor Raza Mirza, MD, of Rigshospitalet, Copenhagen University Hospital, discusses phase III study findings on maintenance therapy with niraparib vs placebo in patients with platinu...
Christian U. Blank, MD, PhD, on Melanoma: Initial Data From the OpACIN Trial (German Language Version)
Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses in German study findings on neoadjuvant ipilimumab plus nivolumab in patients with palpable stage III melan...
Katja Weisel, MD, on Multiple Myeloma: Results of the CASTOR Study
Katja Weisel, MD, of the University of Tübingen, discusses study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with relapsed or re...
Philippe Rochigneux, MD, on Solid Tumors: Use of Chemotherapy Near the End of Life
Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses his findings on the high rates of chemotherapy used at the end of life for metastatic sol...
Alexander Eggermont, MD, PhD, on Melanoma: Results From the EORTC 18071 Trial
Alexander Eggermont, MD, PhD, of Gustave Roussy, discusses final overall survival findings on ipilimumab vs placebo after complete resection of stage III melanoma. (Abstract LBA2)
